Table 3.
Inhibitory effects of drugs on alanine aminotransferase (ALT) elevation and hepatic triglyceride (TG) accumulation in mice fed with a steatohepatitis‐inducing high‐fat diet (STHD‐01) for 1 week
| Drug evaluated | Dose | Inhibitory effect | |
|---|---|---|---|
| ALT elevation | Hepatic TG accumulation | ||
| Telmisartan | 5 mg/kg | ++ | + |
| Olmesartan | 3 mg/kg | + | + |
| Ezetimibe | 10 mg/kg | + | + |
| Vitamin E | 500 mg/kg | + | − |
| Obeticholic acid | 10 mg/kg | ± | ± |
| Rolipram | 30 mg/kg | − | + |
| Pentoxifylline | 50 mg/kg | − | − |
| Pioglitazone | 10 mg/kg | − | − |
| Ursodeoxycholic acid | 360 mg/kg | − | N.A. |
| Eicosapentaenoic acid | 4000 mg/kg | − | − |
| Branched‐chain amino acids | 4200 mg/kg | − | − |
For each drug, the effect was evaluated in a different number of samples, as follows: telmisartan, n = 5–8 (multiple experiments); olmesasrtan, n = 5; ezetimibe, n = 5; vitamin E, n = 7; obeticholic acid, n = 8; rolipram, n = 6; pentoxifylline, n = 7; pioglitazone, n = 5; ursodeoxycholic acid, n = 5; eicosapentaenoic acid, n = 7; and branched‐chain amino acids, n = 8.
For each drug, the effect is expressed as STHD‐01 versus STHD‐01 + drug.
Significance indicators: +, P < 0.05 or P < 0.01; ++, P < 0.001; ±, tendency; −, not significant; N.A., not analyzed (Student's t‐test or Dunnett's test).